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S U M M A R Y
Objectives: A main determinant of clinical response to antibiotic treatment is drug concentration at the
infected site. Data on ceftriaxone (CFX) bone penetration are lacking. We measured CFX concentrations
in infected bone to verify their relationship with pharmacodynamic microbiological markers.
Methods: Eleven patients undergoing debridement for septic non-union of the tibia and receiving
intravenous CFX were studied. Plasma and bone specimens were collected intraoperatively at a variable
interval after CFX administration. Drug concentrations were measured by high-performance liquid
chromatography with ultraviolet detection (HPLC-UV) method.
Results: Bone samples were extracted at a mean of 3.3 h (range 1.5–8.0 h) since the start of CFX infusion.
The mean  standard deviation intraoperative CFX plasma concentration was 128.4  30.8 mg/l; the
corresponding bone concentrations were 9.6  3.4 mg/l (7.8%) in the cortical compartment and
30.8  8.6 mg/l (24.3%) in the cancellous compartment. The mean 24-h area under the concentration–
time curve (AUC24) values were 176.8  62.2 h*mg/l in cortical bone and 461.5  106.8 h*mg/l in cancellous
bone. The time above the minimum inhibitory concentration (T>MIC) was 24 h in all compartments. The
estimated mean free AUC/MIC ratios and T>MIC were 140 and 24.4 h, respectively, in cancellous bone and
42.4 and 21 h, respectively, in cortical bone.
Conclusions: CFX bone penetration was poor (<15%) in the cortical compartment and satisfactory in the
more vascularized cancellous bone. The T>MIC and AUC/MIC ratios suggest that CFX achieves a
satisfactory pharmacokinetic exposure in cancellous bone as far as pathogens with a MIC of <0.5 are
concerned. However, considering free drug concentrations, pharmacokinetic/pharmacodynamic targets
may not be fully achieved in cortical bone. As antibiotic exposure can be suboptimal in the infected
cortical compartment, and drug penetration may be impaired into necrotic bone and sequesters, a
radical surgical removal of purulent and necrotic tissues appears essential to shorten treatment duration
and to prevent treatment failures.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In spite of medical progress, the management of bone and joint
infections remains problematic, requiring prolonged courses of
parenteral antibiotics and surgical debridement in most cases.
Bone infections tend to involve sites of relatively poor vascularity
and are mainly caused by Gram-positive organisms, especially
staphylococci, although Gram-negative agents may also play a
relevant role.1–3
Given their broad spectrum of activity, third-generation
cephalosporins are commonly used to treat osteoarticular infec-
tions either as a single regimen or in association with an anti-* Corresponding author. Tel.: +39 333 2466363; fax: +39 011 3135015.
E-mail address: silvia.garazzino@inwind.it (S. Garazzino).
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doi:10.1016/j.ijid.2011.03.003staphylococcal agent. Intravenous antimicrobial treatment of
osteomyelitis increasingly takes place in outpatient settings; in
this context, ceftriaxone (CFX) as once-daily treatment is a
valuable option, given its unique pharmacokinetics, with pro-
longed plasma half-life, and broad spectrum of activity, including
against community-acquired bacteria involved in post-traumatic
and/or hematogenous osteomyelitis.4
A major determinant of the clinical response to antimicrobial
treatment is the drug concentration at the infected site.5,6 In
infected bone, activation of the inflammatory process may result
initially in increased vascular permeability, with local edema,
followed by impaired blood supply, necrosis and sequester
formation; in the latter situation, antimicrobial penetration may
be inefficient and surgery may become essential. The study of
antimicrobial penetration into infected bone after multiple dosing
better estimates the in vivo situation under infection and mayses. Published by Elsevier Ltd. All rights reserved.
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choice of antimicrobials. Data on CFX penetration into human bone
are limited andmost come from studies on prophylaxis rather than
on therapy, as antibiotic penetration into non-infected human
bone has been evaluated on samples collected during knee or hip
arthroplasty after a single preoperative dose of antimicrobial.
Furthermore, differences in terms of general methodology, drug
extraction, and measurement make these studies difficult to
compare.
We undertook a clinical pharmacokinetic study on patients
with septic pseudoarthrosis receiving CFX as a part of the
antimicrobial treatment, in order tomeasure bone CFX penetration
under steady-state conditions and verify the relationship between
tissue concentrations and the minimum inhibitory concentration
(MIC) of the infecting agents.
2. Materials and methods
2.1. Patients
Adult orthopedic patients undergoing surgical debridement for
septic non-union of the tibia with resection of infected and necrotic
bone and treated for more than 1 week with intravenous CFX were
studied. A patient was included in the present study when all of the
following criteriaweremet: (1) The patient should have clinical and
radiological evidence of septic pseudoarthrosis, defined as the
presence of inflammation or fistula in the area of a previous bone
fracture, radiological non-union of the bone involved, and/or the
presence of biological inflammatory syndrome. Biological inflam-
matory syndrome included an erythrocyte sedimentation rate (ESR)
of >50mm/h and elevated levels (>10 mg/dl) of C-reactive protein
(CRP). (2) Indication for surgical debridement of infected/necrotic
bone and external fixation treatment. (3) The patient should be on
current intravenous antibiotic treatment with CFX at the time of
surgical intervention, of at least 7 days duration, to guarantee the
steady-state attainment; antibiotic treatment should respond to
‘‘best practice and standard of care guidelines’’ as to indication and
dosage.7,8 Exclusion criteria were moderate to severe renal or
hepatic impairment, intolerance or contraindication to the use of
cephalosporins, and infection sustainedbyCFX-resistant pathogens.
At the time of inclusion, demographic, clinical, and radiological
data were registered, including co-morbidities, concomitant
treatments, weight and height. Laboratory data, collected both
prior to and after surgery, included blood and differential counts,
kidney and liver function tests, ESR, CRP, total proteins and
albumin levels. The study period started in January 2006 and ended
in January 2009. The studywas performed according to the current
revised version of the Declaration of Helsinki, and written
informed consent was obtained from each patient. The study
was a non-interventional one. The paper was reviewed and
approved by the local institutional review board.
2.2. Sample collection
Bone specimens were collected during surgical debridement of
necrotic and infected tissue, at a variable interval from the start of
antibiotic infusion, depending upon surgical timing. Simulta-
neously with bone resection, peripheral venous blood samples
were collected using 7-ml lithium–heparin BD Vacutainer system
vials. The amount of tissue vascularization and the eventual
presence of avascular bone were determined by histopathological
analysis of a fragment of collected bone; on the basis of the results,
necrotic tissues and sequesters were excluded from evaluation.
Another bone sample was cultured for microbiological assays and
etiological determination. Clinical specimens were processed
using standard microbiological procedures. Species identificationof the isolates was performed using the API 20E gallery
(BioMe´rieux, Marcy l’Etoile, France), routinely used in our
laboratory. Antimicrobial susceptibility tests of all isolates was
confirmed with the disk diffusion method, and results were
evaluated according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines.9
Serum was obtained by blood centrifugation at 3000 rpm for
10 min and was stored at20 8C prior to assay. Bone samples used
for pharmacokinetic analysis were dissected into cortical and
cancellous bone, washed for 10 s with 10 ml of sterile saline to
remove blood and coagules, blotted dry and stored at80 8C. Bone
marrow was extracted and was not analyzed.
At the time of analysis, cortical specimens were defrosted,
cleaned of soft tissue, and crushed into powderwith an analyticmill
(IKA A11 basic; IKAWerke, GmbH, Staufen, Germany). Cancellous
bone samples were thawed and ground up using a porcelain pestle
and mortar. Crushing procedures consisted of 15-min grinding
cycles, at intervalsof10 seach, toavoid temperature increasesabove
the thermal stability threshold of CFX. For both cortical and
cancellous bone, several samples of 500 mg were weighed with a
precision electronic balanceand transferred into2.5-mlplastic vials.
To quantify CFX in plasma and bone, a fully validated high-
performance liquid chromatography (HPLC) assay was used.
2.3. Stock solutions, plasma standards, and quality controls
CFX stock solutions were prepared in water at a concentration
of 1 mg/ml. Standard samples were prepared by serial dilutions of
the highest standard prepared after addition of determined
volumes of stock solutions to blank plasma. Calibration curves
ranged from 250 mg/l to 0.97 mg/l. To improve the accuracy and
precision of the method, three levels of quality control (high,
medium and low) were prepared by successive dilutions of stock
solutions with blank plasma.
2.4. Bone standards and quality controls
Similarly to plasma, the unknown bone sample concentration
was calculated from a linear calibration curve. To obtain standard
bone samples, the stock solution of each drug was diluted in blank
weighed bone. Calibration curves of five points, including blank
bone, were obtained from standard samples and ranged from
25 mg/g to 3mg/g. Three levels of bone quality control were
prepared: high, medium and low.
2.5. HPLC equipment
The chromatography apparatus was a Merck–Hitachi LaChrom
(Tokyo, Japan), with a pumpmodel L-7100, an L-7200 autosampler,
an L-7400 ultraviolet detector, and D-7000 interface. HPLC System
Manager software (HSM version 4.1; Merck–Hitachi, Tokyo, Japan)
was used for managing the HPLC system. Chromatographic
separation was performed by Atlantis 3m C18 column
(150  4.6 mm i.d.; Waters SpA, Milan, Italy) protected by C18
Security-Guard (4.0  3.0 mm i.d.; Phenomenex, CA, USA) at 35 8C,
using a column thermostat L-7350 Merck–Hitachi LaChrom. Assay
separation was achieved by gradient elution and the mobile phase
was composed of buffer A (KH2PO4 50 mM) and acetonitrile as
buffer B. The flow ratewas set at 1 ml/min. The UV detector was set
at 274 nm, which is the best wavelength in terms of selectivity and
sensibility for CFX analysis.
2.6. Ceftriaxone assay
Plasma samples were prepared by mixing 200ml of plasma
with 600 ml of acetonitrile and 50 ml of internal standard (IS)
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daily). After vortexing for at least 10 s and centrifugation at
12 000 rpm for 10 min at 4 8C, 400ml of supernatant was diluted
with 400 ml of water, and 50 ml of sample was injected into the
HPLC system. Bone samples were mixed with 50 ml of IS and with
1 ml of sodium phosphate buffer pH 7 (Sigma-Aldrich, Italy).
Samples were vortexed for 10 s and tumbled for 5 h at 25 rpm at
4 8C. After centrifugation at 12 000 rpm for 10 min at 4 8C, 20ml of
supernatant was injected into the HPLC apparatus. The calculation
method was based on peak areas and on internal standard ratio;
the type of calibration curve selected was ‘‘linear and forced
through zero’’. The retention time of CFXwas 8.2 ( 0.2)min and for
IS was 3.8 ( 0.2) min. Accuracy, intra- and inter-day variability
expressed as coefficient of variation % (CV%) were respectively 5.2%,
3.6% and 4.5% for plasma samples, and 7.2%, 7.8% and 10.3% for bone
samples. Recovery was 86% (CV% = 3) for bone samples and 82%
(CV% = 8) for plasma samples. Detection limits for the CFX assay in
plasma and bone were 0.24 mg/l and 0.5 mg/l, respectively.
The amount of antibiotic recovered in bone samples due to
blood contamination was calculated as previously described,10,11
with the following formula:
Blood contaminationð%Þ ¼ K Hb in supernatant
Hb in blood
ð100HctÞ;
where Hb is hemoglobin (g/dl), K the dilution factor corresponding
to the mean volume of water displaced by 1 g of bone (1/bone
density) and measuring 0.83 ml for cortical bone and 2 ml for
cancellous bone,10 and Hct is the hematocrit (%). The net bone
concentration was obtained by subtracting blood contamination
from the value measured in bone samples.
Antibiotic concentrations were measured in duplicate in
adjacent bone samples and then averaged to improve the accuracy
of the assays.
2.7. Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis of the data was
performed using the WinNonlin software program (WinNonlin
version 5.2; Pharsight Corp., Mountain View, CA, USA). For each
patient, drug concentrations measured in plasma and bone were
plotted against time of sampling. The first-order approximation
was used to derive ‘population pharmacokinetic’ parameters, such
as CFX half-life; the maximum concentrations (Cmax) and mini-
mum concentrations (Cmin) in plasma and bonewere subsequently
obtained from the known data. The 24-h area under the
concentration–time curve (AUC24) in plasma and bone was
calculated by linear-log trapezoidal rule.Table 1
Demographic characteristics of the study population
Patient
number
Age
(years)
Weight
(kg)
Height
(m)
BMI Days of
treatmenta
C
1 18 46 1.62 17.53 9 C
2 41 75 1.80 23.15 17 A
3 30 65 1.65 23.88 11 -
4 24 83 1.82 25.06 10 -
5 38 73 1.76 23.57 18 H
6 36 81 1.78 25.56 8 -
7 38 79 1.72 26.70 12 -
8 33 77 1.80 23.77 32 -
9 29 73 1.74 24.11 30 -
10 65 80 1.65 29.38 15 D
11 64 70 1.60 27.34 12 H
Mean 37.8 72.9 1.72 24.55 15.8
BMI, body mass index; LMW, low molecular weight; HCV, hepatitis C virus.
a Duration of antibiotic treatment with ceftriaxone before sampling.2.8. Statistical analysis
Statistical analysis was performed using PASW Statistics
version 17.0 (IBM SPSS, Chicago, IL, USA). Statistical decisions
were made at p = 0.05. All p-values were two-tailed. To evaluate
linear relationships, Pearson and Spearman correlation tests were
used.
3. Results
Eleven male patients were studied; their mean age was 37.8
years (range 18–65 years). Demographic characteristics of the
study population are shown in Table 1.
All patients received intravenous CFX 2 g daily administered
over a 30-min infusion for post-traumatic septic non-union of the
diaphyseal tibia and underwent surgical debridement of infected
and necrotic bone. Mean duration of treatment before sampling
was 15.8 days. Bone cultures grew methicillin-sensitive Staphylo-
coccus aureus (MSSA) in four cases, Staphylococcus epidermidis
(MSSE) and Serratia marcescens in two cases each, and Citrobacter
freundii, Klebsiella oxytoca and Escherichia coli in the remaining
patients. All isolates were sensitive to CFX (MIC <2 mg/l).
Bone samples were extracted at a mean of 3.3 h (range 1.5–
8.0 h) since the start of CFX infusion. Median and mean  standard
deviation (SD) CFX plasma concentrations at the time of osteotomy
were 118.5 and 128.4  30.8 mg/l, respectively. Median and
mean  SD bone concentrations were 9.1 and 9.6  3.4 mg/l,
respectively, in cortical bone and 28.4 and 30.8  8.6 mg/l, respec-
tively, in cancellous bone. The mean bone/plasma concentration ratio
was 7.8% for cortical bone and 24.3% for cancellous bone (Table 2). The
distribution of plasma and bone CFX concentrations and of bone/
plasma ratios over time are illustrated in Figures 1 and 2.
The mean peak concentration in plasma (Cmax), derived by a
population pharmacokinetic analysis, was 191.6 mg/l; the mean
plasma volume of distribution at steady state (Vss) was 9.06 l. The
plasma half-life was 5.9 h; the lambda z was 0.1175 l1. The
median and mean  SD plasma AUC24 were 1902.1 and
1930.5  310.8 h*mg/l, respectively. The median and mean  SD
bone AUC24 were 163.2 and 176.8  62.2 h*mg/l, respectively, for
cortical bone, and 459.4 and 461.5  106.8 h*mg/l, respectively, for
cancellous bone. Bone half-life was 16.6 h in cortical and 7.3 h in
cancellous bone.
The median and mean  SD values for CFX AUC24 bone/plasma
ratio were 9.1% and 9.3  3.2%, respectively, for cortical bone and
24.2% and 24.1  5.1%, respectively, for cancellous bone (Table 3). The
mean overall drug exposure in cancellous bone was three times
higher than in cortical bone. MICs of infecting bacteria ranged
between 0.25 and 0.5 mg/l. Themean CFX concentration over theMICo-morbidity Co-medication
rohn’s disease Analgesics, LMW heparin, prednisone
sthma Analgesics, LMW heparin, salmeterol, fluticasone
Analgesics, LMW heparin
Analgesics, LMW heparin
CV infection Analgesics, LMW heparin
Analgesics, LMW heparin
Analgesics, LMW heparin
Analgesics, LMW heparin
Analgesics, LMW heparin
yslipidemia Analgesics, LMW heparin pravastatin
ypertension Analgesics, LMW heparin, olmesartan/hydrochlorothiazide
Table 2
Ceftriaxone concentrations in plasma and cortical and cancellous bone
Patient
number
Time of
sampling
(min)a
Plasma
concentration
(mg/l)
Cortical bone
concentration
(mg/l)
Cancellous bone
concentration
(mg/l)
Cortical bone/
plasma ratio (%)
Cancellous
bone/ plasma
ratio (%)
Blood
contamination
cortical bone (%)
Blood
contamination
cancellous bone (%)
1 90 195.97 6.95 35.65 3.54 18.19 0.67 3.21
2 120 166.11 17.28 36.84 10.40 22.18 1.05 8.89
3 135 142.16 6.08 38.08 4.27 26.78 0.82 3.96
4 150 133.85 5.68 49.42 4.24 36.92 1.75 8.44
5 150 129.12 9.72 31.11 7.53 24.09 1.34 9.89
6 165 110.02 13.48 27.57 12.25 25.06 1.34 9.89
7 180 109.93 11.64 28.43 10.59 25.86 1.46 10.55
8 210 118.34 9.44 22.83 7.97 19.29 1.54 4.21
9 225 118.50 9.10 20.58 7.68 17.36 1.43 4.30
10 270 98.80 7.54 25.17 7.63 25.47 1.55 2.49
11 480 89.52 8.83 22.99 9.86 25.69 0.22 5.34
Mean 197.7 128.39 9.61 30.79 7.82 24.26 1.17 6.09
Median 165 118.5 9.10 28.43 7.68 25.06 1.34 5.34
a Time past start of infusion (duration of infusion=30min).
[(Figure_2)TD$FIG]
Figure 2. Ceftriaxone bone/plasma ratios vs. time.
[(Figure_1)TD$FIG]
Figure 1. Ceftriaxone concentrations in plasma and bone vs. time.
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Mean CFX AUC24/MIC ratioswere 4516.7 for plasma, 400.1 for cortical
bone, and 1092.6 for cancellous bone. CFX concentrationswere higher
than the MIC of the infecting agent for the entire dosing interval in all
compartments evaluated.
Assuming unbound CFX to be about 10% of the total, the
estimated mean free AUC was 56.1 h*mg/l in cancellous bone and
17.9 h*mg/l in cortical bone; the corresponding mean free AUC/Table 3
Ceftriaxone pharmacokinetic parameters in plasma and cortical and cancellous bone
Patient
number
Plasma
Vss (l)
Plasma
AUC24 (h*mg/l)
Cortical
bone AUC24
(h*mg/l)
1 8.39 2628.23 128.86
2 10.55 2290.79 331.96
3 7.48 1989.71 118.74
4 9.46 1902.06 112.93
5 9.23 1956.32 178.21
6 7.91 1614.04 214.40
7 7.43 1613.10 213.14
8 11.20 1796.33 163.19
9 10.53 1799.83 162.02
10 8.95 1616.56 137.04
11 8.56 2028.80 184.51
Mean 9.06 1930.53 176.82
Median 8.95 1902.06 163.19
Vss, mean plasma volume of distribution at steady-state; AUC24, 24-h area under the cMIC ratios and T>MIC were 140 and 24.4 h, respectively, in
cancellous bone and 42.4 and 21 h, respectively, in cortical bone.
Nine patients were clinically and radiologically cured at the
latest follow-up visit. One patient (patient 11) underwent a leg
amputation and one (patient 7) had chronic osteomyelitis.
3.1. Statistical analysis
Statistically significant results of the correlation analysis are
listed in Table 5.
Pearson’s correlation coefficient indicated a statistically signifi-
cant linear relationship between CFX cortical bone concentrationsCancellous
bone AUC24
(h*mg/l)
Cortical
AUC/ plasma
AUC (%)
Cancellous
AUC/ plasma
AUC (%)
536.24 4.90 20.40
496.76 14.49 21.69
528.78 5.97 26.58
697.10 5.94 36.65
459.43 9.11 23.48
405.36 13.28 25.11
406.84 13.21 25.22
326.33 9.08 18.17
325.13 9.00 18.06
404.07 8.48 25.00
490.22 9.09 24.16
461.48 9.32 24.05
459.43 9.08 24.16
oncentration–time curve; AUC, area under the curve.
Table 4
Ceftriaxone bone concentration/MIC ratios for Gram-positive and Gram-negative isolates
Patient
number
Pathogen Ceftriaxone MIC Cortical bone
concentration/
MIC
Cancellous bone
concentration/
MIC
Plasma
AUC/MIC
Cortical
bone
AUC/MIC
Cancellous
bone AUC/ MIC
Cortical
bone
T>MIC (h)
Cancellous
bone
T>MIC (h)
1 E. coli 0.5 13.89 71.31 5256.47 257.72 1072.47 24 24
2 MSSA 0.5 34.56 73.67 4581.58 663.92 993.53 24 24
3 MSSA 0.25 24.30 152.30 7958.84 474.97 2115.13 24 24
4 MSSA 0.5 11.36 98.83 3804.13 225.85 1394.19 24 24
5 C. freundii 0.5 19.44 62.22 3912.64 356.42 918.86 24 24
6 MSSE 0.5 26.95 55.14 3228.08 428.79 810.71 24 24
7 S. marcescens 0.5 23.28 56.86 3226.21 426.28 813.67 24 24
8 S. marcescens 0.5 18.87 45.67 3592.67 326.37 652.67 24 24
9 MSSE 0.5 18.20 41.15 3599.67 324.04 650.27 24 24
10 MSSA 0.25 30.17 100.66 6466.24 548.17 1616.29 24 24
11 K. oxytoca 0.5 17.66 45.99 4057.60 369.03 980.43 24 24
Mean 21.7 73.07 4516.74 400.14 1092.57 24 24
MIC, minimum inhibitory concentration; AUC, area under the curve; T>MIC, time above the MIC; MSSA, methicillin-sensitive Staphylococcus aureus; MSSE, methicillin-
sensitive Staphylococcus epidermidis.
Table 5
Statistically significant correlations
Variable Associated variables r p-Value
Plasma concentration Weight 0.692 0.027
BMI 0.907 0.000
Plasma AUC24 0.849 0.002
Cortical bone concentration WBC 0.924 0.000
ESR 0.694 0.026
Cortical bone/plasma ratio 0.807 0.005
Cortical bone AUC24 0.973 0.000
Cancellous bone concentration Cancellous bone/plasma ratio 0.648 0.043
Cancellous bone AUC24 0.909 0.000
Cortical bone/plasma ratio WBC 0.737 0.015
Cortical bone concentration 0.807 0.005
Cortical bone AUC24 0.747 0.013
Cancellous bone/plasma ratio Cancellous bone concentration 0.648 0.043
Cancellous bone AUC24 0.713 0.021
Plasma AUC24 Plasma concentration 0.849 0.002
Weight 0.823 0.003
BMI 0.814 0.004
Cortical bone AUC24 WBC 0.932 0.000
ESR 0.777 0.008
CRP 0.694 0.026
Cortical bone concentration 0.973 0.000
Cortical bone/plasma ratio 0.747 0.013
Cancellous bone AUC24 Cancellous bone concentration 0.909 0.000
Cancellous bone/plasma ratio 0.713 0.021
BMI, body mass index; AUC24, 24-h area under the concentration–time curve; WBC, white blood cell count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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bone AUC and all inflammatory indices, and finally between
cortical bone penetration and WBC. Plasma CFX concentrations
and plasma AUC were inversely related to body weight and body
mass index (BMI).
Both in the univariate andmultivariate analysis, CFX cancellous
bone concentrations and cancellous bone AUC were directly
related to time of collection, ESR, and CRP.
4. Discussion
CFX is frequently used in the treatment of osteoarticular
infections, given its broad spectrum of activity, unique pharmaco-
kinetics, and good tolerability. Major aspects of CFX pharmacoki-
netics include a high serum protein binding and a long half-life of 6
to 9 h; the latter allows a once-daily dosing regimen, which is
greatly responsible for CFX cost-effectiveness when compared to
other third- and fourth-generation cephalosporins. CFX binds
tightly to albumin with a serum binding ratio far higher than that
observed for most third- and fourth-generation cephalosporins
(nearly 95% versus 10–40%); however, CFX protein binding is
reversible and saturable, meaning that the binding decreases withincreasing plasma concentrations.12,13 CFX is active against
community-acquired Gram-positive bacteria, but also against
numerous Gram-negative agents that may be involved in post-
traumatic and/or hematogenous osteomyelitis.
Although drug penetration in infected tissues is critical for
efficacy, the knowledge on pharmacokinetics of antimicrobials in
the bone compartment is rather sparse. To the best of our
knowledge, there are three studies concerning bone penetration of
CFX administered for surgical prophylaxis. Scaglione et al.
measured CFX concentrations in uninfected bone of patients
undergoing hip arthroplasty: CFX concentrations in cancellous and
cortical bone were dramatically lower than total serum levels, but
comparable to serum free levels; maximum observed CFX
concentrations were 10.7 and 19.4 mg/kg of body weight in
cortical and cancellous bone, respectively, 2.5 h after antibiotic
administration.14 Lovering et al. measured bone concentrations of
CFX and cefamandole administered simultaneously before total
hip replacement: CFX and cefamandole mean bone penetration
appeared similar (15.6% vs. 18.4%), providing no evidence that
cephalosporins with lower serum protein binding penetrate bone
better than ones with higher protein binding.15 Finally, Soudry
et al. reported CFX penetration rates varying between 5% and 8% in
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studies are available concerning CFX penetration into infected
bone. In the present study, 11 patients with rather comparable
forms of septic non-union of the tibia were investigated. At the
time of pharmacokinetic sampling all patients were receiving CFX
and were pharmacologically classified as being at steady-state. We
analyzed CFX concentrations reached in both cortical and
cancellous infected bone using a standard validated HPLC method.
Necrotic bone samples and sequesters were not included in the
analysis, considering that tissue drug delivery may be affected by
impaired blood supply (e.g., peripheral ischemia). The mean CFX
bone/plasma rate varied according to the compartment consid-
ered: cancellous bone/plasma concentration and AUC ratios were
roughly three times higher than the cortical ones. The anatomic
difference in vascularization between the two bone compartments
may partly explain the difference observed: cancellous bone has a
rich capillary bed and a relatively small volume of interstitial fluid,
and drugs readily diffuse across the capillary surface area;
conversely, the penetration of antibiotics into cortical bone occurs
exclusively through the bone marrow or periosteal circulation and
is expected to be lower than in cancellous bone.
A due consideration in the analysis of drug bone penetration is
that single point measurement of bone/plasma ratios may yield
significantly different results depending upon the time of
sampling: after intravenous administration of an antimicrobial,
tissue distribution occurs, but the shape of the concentration vs.
time curves of plasma and tissue compartments may differ
substantially due to delayed equilibrium between the two
compartments.17 To better estimate bone drug exposure of CFX,
we modeled our data using an extrapolation approach: from
plasma and bone concentrations measured at different intervals
from drug administration we inferred the AUC0–24 values for
plasma and for the two bone compartments, and we estimated
bone penetration according to the respective AUC ratios.
Analyzing our results according to the classification proposed
by Boselli et al.,18 CFX can be placed among the antibiotics with
satisfactory bone penetration (rates between 15% and 30%) when
considering cancellous bone, and within the group with poor bone
penetration (<15%) when considering cortical bone. The review
published in 1999 by Boselli et al. attributed a medium bone
penetration to CFX, as to second- and third-generation cephalos-
porins in general; however, heterogeneous studies were analyzed
and cortical and cancellous bone were seldom differentiated.
In our study, inter-individual variability observed in cortical
and cancellous bone concentrations may be accounted for by the
different intensity of the inflammatory process in bone samples
and the different timing of bone collection. Bone concentrations
were found to have no association with individual variables like
age, body weight, height and BMI, while an association was found
in some cases between bone concentrations and inflammatory
markers, perhaps as a result of increased vascularization and
vascular permeability under inflammation conditions.
Tissue penetration is an estimate of the capacity of an
antimicrobial to reach the site of infection. However, in the choice
of the optimal antimicrobial treatment, other factors should be
considered. The bacterial sensitivity to antimicrobials is expressed
by parameters such as the MIC and the inhibitory quotient (IQ), the
latter being the ratio between concentration and MIC. The IQ
provides indicationsonantibiotic activityataprecise siteof infection
against a certain microorganism and thus on the probability of
therapeutic success; therefore, the IQ is a rough estimate of the
antimicrobial efficacy, but its valuemayvary according to the timeat
which antimicrobial concentration is measured.19The percentage of
time above the MIC (%T>MIC) is regarded as the best pharmacoki-
netic/pharmacodynamic (PK/PD) parameter for predicting the
clinical efficacy ofb-lactams. CFX displays a time-dependent killing,and time to bacterial eradicationhas been demonstrated to correlate
with the time above the MIC (T>MIC) and the area under the
inhibitory time curve (AUIC, or AUC/MIC). The pharmacodynamic
properties of CFX have been investigated in different populations,
including healthy volunteers, children, the elderly, and patientswith
renal and hepatic impairment, against various Gram-positive
bacteria. Target free AUIC values of at least 125 have been suggested
for patients with severe infections.20–23
It is very likely that the same PK/PD indices also apply to bone
infections, even if PK/PD targets have not yet been identified. In our
study the %T>MIC corresponded to 100% of the dosing interval for
total drug concentrations. Assuming unbound CFX to be about 10%
of the total,13 estimated mean free AUC/MIC ratios and T>MIC
were respectively 140 and 24.4 h in cancellous bone and 42.4 and
21 h in cortical bone, suggesting that CFX achieves a satisfactory
exposure in cancellous bone, as far as susceptible pathogens are
considered. In contrast, CFX PK/PD targets may not be fully
achieved in cortical bone, where exposure may be suboptimal.
The majority of our patients were clinically and radiologically
cured at the latest follow-up visit. The recovery of bacteria in bone
samples aftermore than 8 days of CFX treatmentmay be accounted
for by the metabolically quiescent status and low replication rate
that often characterize bone-infecting organisms; however, this
underlines the importance of a proper and early surgical removal
of infected bone. Indeed, treatment of osteomyelitis typically
requires prolonged courses of antibiotics associated with a radical
surgical debridement. The correlation between CFX bone concen-
tration and microbiological outcome is yet to be established.
Our study has several main limitations, the first of which is the
lack of a control group of non-infected human bone. The second is
the different post-dose timing in bone collection, which was
determined by individual surgical reasons, and the availability of a
single measurement from each compartment. Third, although all
samples were extracted from the same bone segment (tibia),
differences in the local degree of vascularization and inflammation
can account for some inter-individual variability in CFX bone
concentrations. Finally, the method of drug extraction from bone
samples has intrinsic limitations and does not differentiate intra-
and extra-cellular compartments; incomplete extraction and
consequent underestimation cannot be excluded. Drug removal
during samplewashingwasminimized by the short duration of the
procedure; drug levels in the washing fluid were in all cases under
the detectability level. Drug degradation may occur during
grinding without cooling; we thus performed short-term crushing
cycles to avoid temperatures rising up to the CFX thermal
instability threshold. The size of the study population appears to
be clinically relevant in consideration of the small case-series so far
reported in the literature.
In conclusion, the analysis of the degree of penetration of
antimicrobials into infected tissues aims at giving clinicians
additional information on which to base the choice of the optimal
antibiotic treatment. In our study, CFX displayed a poor penetra-
tion into septic cortical bone, while bone penetration was
satisfactory into the highly vascularized cancellous bone. As
antibiotic exposure can be suboptimal in the infected cortical
compartment, and drug penetrationmay be impaired into necrotic
bone and sequesters, a radical surgical removal of purulent and
necrotic tissues appears essential to shorten treatment duration
and to prevent treatment failures.
Conflict of interest: No conflict of interest to declare.
References
1. Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Mandell GL, Bennett
JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed., New
York: Churchill Livingstone; 2005. p. 1323–32.
S. Garazzino et al. / International Journal of Infectious Diseases 15 (2011) e415–e421 e4212. Cierny G,Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis.
Clin Orthop Relat Res 2003;414:7–24.
3. Lieberman JR, Callaway GH, Salvati EA, Pellicci PM, Brause BD. Treatment of the
infected total hip arthroplasty with a two stage reimplantation protocol. Clin
Orthopaed Related Res 1994;301:205–12.
4. Guglielmo BJ, Luber AD, Paletta D, Jacobs RA. Ceftriaxone therapy for staphylo-
coccal osteomyelitis: a review. Clin Infect Dis 2000;30:205–7.
5. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob
Agents Chemother 1988;32:289–97.
6. Redington J, Ebert SC, Craig WA. Role of antimicrobial pharmacokinetics and
pharmacodynamics in surgical prophylaxis. Rev Infect Dis 1991;13(Suppl
10):790–9.
7. Tsukayama DT, Guay DR, Peterson PK. Antibiotic therapy of chronic
osteomyelitis. In: Gustilo RB, Gruninger RP, TsukayamaDT, editors.Orthopaedic
infection: diagnosis and treatment. Philadelphia, PA: Saunders; 1989. p. 166–74.
8. Darley ES, MacGowan AP. Antibiotic treatment of Gram-positive bone and joint
infections. J Antimicrob Chemother 2004;53:928–35.
9. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. Eighteenth informational supplement. M100-S18
Vol. 28, No. 1. Wayne, PA: CLSI; 2008.
10. Djabarouti S, Boselli E, Allaouchiche B, Ba B, Nguyen AT, Gordien JB, et al.
Determination of levofloxacin in plasma, bronchoalveolar lavage and bone
tissues by high-performance liquid chromatography with ultraviolet detection
using a fully automated extraction method. J Chromatogr B Analyt Technol
Biomed Life Sci 2004;799:165–72.
11. Roncoroni AJ, Manuel C, Nedjar C, Bauchet J, Mariani D. Cefamandole bone
diffusion in patients undergoing total hip replacement. Chemotherapy
1981;27:166–72.
12. Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal Jr JJ. Phar-
macokinetic characteristics of intravenous ceftriaxone in normal adults. Anti-
microb Agents Chemother 1982;22:816–23.
13. Hamilton RA, Kowalsky SF, McCormick EM, Echols RM. Protein binding of
ceftriaxone, cefoperazone, and ceftizoxime. Clin Pharm 1987;6:567–9.14. Scaglione F, DeMartini G, Peretto L, Ghezzi R, Baratelli M, ArcidiaconoMM, et al.
Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of
patients undergoing hip arthroplasty. Antimicrob Agents Chemother 1997;
41:2292–4.
15. Lovering AM, Walsh TM, Bannister GC, MacGowan AP. The penetration of
ceftriaxone and cefamandole into bone, fat and haematoma and relevance of
serum protein binding to their penetration into bone. J Antimicrob Chemother
2001;47:483–6.
16. Soudry B, Sirot J, Lopitaux R, Dumont C, Delisle JJ, Parenton M. Diffusion de la
ceftriaxone dans le tissue osseux humain. Pathol Biol 1986;34:859–62.
17. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O.
Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008;61:
235–7.
18. Boselli E, Allaouchiche B. Diffusion osseuse des antibiotiques. Presse Med
1999;28:2265–76.
[19] Goldstein F. Sensibilite´ et re´sistance des souches—quotients inhibiteurs, In:
Mainardi JL, editor. Pre´cis d’antibiothe´rapie pratique. Phase 5, Paris, France;
1995. p. 81–147.
20. Ohno A, Ishii Y, Kobayashi I, Yamaguchi K. Antibacterial activity and PK/PD of
ceftriaxone against penicillin-resistant Streptococcus pneumoniae and b-lacta-
mase-negative ampicillin-resistant Haemophilus influenzae isolates from
patients with community-acquired pneumonia. J Infect Chemother 2007;
13:296–301.
21. Perry TR, Schentag JJ. Clinical use of ceftriaxone: a pharmacokinetic–pharma-
codynamic perspective on the impact of minimum inhibitory concentration
and serum protein binding. Clin Pharmacokinet 2001;40:685–94.
22. Chiu LM, Menhinick AM, Johnson PW, Amsden GW. Pharmacokinetics
of intravenous azithromycin and ceftriaxone when administered alone and
concurrently to healthy volunteers. J Antimicrob Chemother 2002;50:1075–9.
23. Joynt GM, Lipmann J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmaco-
kinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob
Chemother 2001;47:421–9.
